| |
| |
|
| Insider
Information: |
Venkatesan Jay |
| Relationship: |
See Remarks, Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
6,281,269 |
|
|
Indirect Shares
|
14,369,339 |
|
|
| Direct
Value |
$17,523,770 |
|
|
|
Indirect Value
|
$306,612,458 |
|
|
| Total
Shares |
20,650,608 |
|
|
| Total
Value |
$324,136,227 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
9
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
9
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-9.0
|
-2.0
|
| Percentage
Gain/Loss : |
 -53.9%
|
-85.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cascadian Therapeutics, Inc |
CASC |
EVP and General Manager |
2014-09-23 |
3,826,723 |
2014-09-23 |
250,000 |
Premium* |
|
|
Abeona Therapeutics Inc |
ABEO |
10% Owner |
|
0 |
2012-06-29 |
2,413,163 |
Premium* |
|
|
Insmed Inc |
INSM |
10% Owner |
|
0 |
2012-09-28 |
3,116,100 |
Premium* |
|
|
Iovance Biotherapeutics Inc |
IOVA |
10% Owner |
|
0 |
2013-05-22 |
5,604,015 |
Premium* |
|
|
Alpine Immune Sciences Inc |
ALPN |
Director, 10% Owner |
2022-07-15 |
238,126 |
2022-07-15 |
2,638,246 |
Premium* |
|
|
Exicure Ord Shs |
XCUR |
Director |
2020-07-06 |
324,473 |
2020-07-06 |
347,815 |
Premium* |
|
|
Elicio Therapeutics Ord Shs |
ELTX |
See Remarks, Director |
2022-05-25 |
1,891,947 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
50 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| IOVA |
Iovance Biotherapeutics I... |
10% Owner |
– – • |
2013-05-22 |
5 |
A |
$4.90 |
$27,444,346 |
I/I |
5,600,887 |
5,604,015 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
EVP and General Manager |
• – – |
2014-08-08 |
4 |
A |
$0.00 |
$0 |
I/I |
263,493 |
263,493 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
EVP and General Manager |
• – – |
2014-08-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,776,723 |
3,826,723 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
EVP and General Manager |
• – – |
2014-09-23 |
4 |
A |
$2.00 |
$500,000 |
I/I |
250,000 |
250,000 |
0 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
President |
• • • |
2017-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,841,172 |
3,803,906 |
0 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
President |
• • • |
2017-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
21,739 |
21,739 |
0 |
- |
|
| XCUR |
Exicure Ord Shs |
Director |
– • – |
2017-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
52,234 |
52,234 |
0 |
- |
|
| XCUR |
Exicure Ord Shs |
Director |
– • – |
2017-09-26 |
4 |
A |
$0.00 |
$0 |
I/I |
281,149 |
90,192 |
0 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • • |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
181,024 |
202,763 |
0 |
- |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2021-02-09 |
4 |
A |
$0.00 |
$3,031 |
D/D |
165,356 |
1,280,348 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
EVP and General Manager |
• – – |
2014-09-23 |
4/A |
B |
$2.00 |
$500,000 |
I/I |
250,000 |
250,000 |
1.99 |
- |
|
| XCUR |
Exicure Ord Shs |
Director |
– • – |
2017-09-26 |
4 |
B |
$3.00 |
$199,998 |
I/I |
66,666 |
156,858 |
2.1 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • • |
2019-01-18 |
4 |
B |
$5.37 |
$1,024,999 |
I/I |
190,875 |
3,994,781 |
2.25 |
- |
|
| XCUR |
Exicure Ord Shs |
Director |
– • – |
2019-08-02 |
4 |
B |
$2.00 |
$500,000 |
D/D |
250,000 |
302,234 |
2.39 |
- |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2021-12-15 |
4 |
B |
$2.41 |
$186,956 |
D/D |
77,604 |
1,316,861 |
2.81 |
% |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2021-12-16 |
4 |
B |
$2.55 |
$70,993 |
D/D |
27,883 |
1,344,744 |
2.81 |
% |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2021-12-17 |
4 |
B |
$2.54 |
$34,958 |
D/D |
13,742 |
1,358,486 |
2.81 |
% |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2021-12-20 |
4 |
B |
$2.54 |
$8,976 |
D/D |
3,527 |
1,362,013 |
2.81 |
% |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2021-12-27 |
4 |
B |
$2.55 |
$170,519 |
D/D |
66,907 |
1,428,920 |
2.81 |
% |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2021-12-28 |
4 |
B |
$2.66 |
$559,854 |
D/D |
210,337 |
1,639,257 |
2.81 |
% |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2022-05-20 |
4 |
B |
$1.23 |
$61,500 |
D/D |
50,000 |
1,689,257 |
2.81 |
% |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2022-05-24 |
4 |
B |
$1.24 |
$39,928 |
D/D |
32,200 |
1,721,457 |
2.81 |
% |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2022-05-25 |
4 |
B |
$1.25 |
$14,103 |
D/D |
11,313 |
1,891,947 |
2.81 |
% |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • • |
2020-12-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(993,801) |
3,000,980 |
0 |
- |
|
| ELTX |
Elicio Therapeutics Ord S... |
See Remarks |
• • – |
2021-02-09 |
4 |
D |
$16.00 |
$511,456 |
D/D |
(31,966) |
1,037,017 |
0 |
- |
|
50 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
